Algert Global LLC Buys 40,489 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Algert Global LLC lifted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 165.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 64,961 shares of the company's stock after purchasing an additional 40,489 shares during the period. Algert Global LLC owned 0.12% of Janux Therapeutics worth $3,478,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. RA Capital Management L.P. raised its holdings in shares of Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock valued at $554,977,000 after purchasing an additional 1,200,000 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after acquiring an additional 986,750 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock worth $59,429,000 after acquiring an additional 950,557 shares during the last quarter. FMR LLC raised its stake in Janux Therapeutics by 10.8% in the 4th quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after acquiring an additional 845,266 shares during the period. Finally, Lord Abbett & CO. LLC lifted its holdings in Janux Therapeutics by 80.2% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,267,803 shares of the company's stock valued at $67,878,000 after purchasing an additional 564,322 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Price Performance

Shares of JANX stock traded down $0.81 on Friday, hitting $25.56. 742,298 shares of the company's stock were exchanged, compared to its average volume of 857,118. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The company has a 50 day moving average of $29.27 and a 200 day moving average of $41.74. The stock has a market cap of $1.51 billion, a P/E ratio of -21.85 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.04. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. purchased 110,206 shares of the firm's stock in a transaction on Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the purchase, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at approximately $2,630,912.17. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,001 shares of company stock valued at $313,964 in the last ninety days. 29.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Scotiabank cut their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. Wedbush reiterated an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Finally, HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and an average target price of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.